Company Profile
Erasca Stock Price, News & Catalysts
- Ticker:
- ERAS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
15.34 USD (-0.13%)
Close
Last updated: September 17, 2026
4.19B USD
Market cap
Why the stock is moving
As of Sep 17, 2026, ERAS was little changed and closed at $15.34. No new same-company headline was identified in the current news window.
Company overview
RAS/MAPK Precision Oncology
Erasca is a clinical-stage precision-oncology company developing therapies for cancers driven by the RAS/MAPK pathway. Its portfolio is designed to address genetically defined tumors through direct RAS inhibition.
ERAS-0015
ERAS-0015 is a pan-RAS molecular glue being evaluated in the AURORAS clinical program. Development includes monotherapy and combination strategies in KRAS-mutated pancreatic, lung, and colorectal cancers.
Registration-Oriented Development
Erasca plans potentially registration-enabling studies of ERAS-0015 in pancreatic and non-small cell lung cancers. The strategy spans later-line monotherapy and frontline combinations.
ERAS-4001
ERAS-4001 is a pan-KRAS inhibitor in the Phase 1 BOREALIS-1 study. The program is intended to broaden treatment coverage across KRAS-driven tumors beyond individual mutation subtypes.
Future catalysts
- Preliminary Phase 1 monotherapy data for ERAS-4001 in the second half of 2026.
- ERAS-0015 Phase 1 monotherapy expansion and combination dose-escalation data in the first half of 2027.
- Initiation of a potentially registration-enabling ERAS-0015 study in second-line or later NSCLC in the first half of 2027.
- Initiation of a Phase 3 ERAS-0015 study in first-line pancreatic ductal adenocarcinoma in 2027.
- Initiation of ERAS-4001 monotherapy expansion and combination dose-escalation cohorts in 2027.
- Initiation of a Phase 3 ERAS-0015 study in RAS-mutated NSCLC between the second half of 2027 and the first half of 2028.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Erasca (ERAS)?
Erasca (ERAS) most recently closed at 15.34 USD, a -0.13% move versus the previous session.
What is the market cap of Erasca (ERAS)?
Erasca currently has a market capitalization of 4.19B USD on BioPharmSignal.
What does Erasca do?
RAS/MAPK Precision Oncology Erasca is a clinical-stage precision-oncology company developing therapies for cancers driven by the RAS/MAPK pathway. Its portfolio is designed to address genetically defined tumors through direct RAS inhibition. ERAS-0015 ERAS-0015 is a pan-RAS molecular glue being evaluated in the AURORAS clinical program. Development includes...
On which exchange is ERAS stock listed?
Erasca (ERAS) is associated with NASDAQ, United States, Biopharma.
What is ERAS-0015?
ERAS-0015 Phase 1 monotherapy expansion and combination dose-escalation data in the first half of 2027.
Which conditions is Erasca targeting with ERAS-0015?
Erasca is associated with oncology, cancer therapeutics, genetic disease based on its company overview and current catalyst commentary.
How does Erasca describe recent progress with ERAS-0015?
ERAS-0015 Phase 1 monotherapy expansion and combination dose-escalation data in the first half of 2027.
What is ERAS-4001?
ERAS-4001 ERAS-4001 is a pan-KRAS inhibitor in the Phase 1 BOREALIS-1 study.